NextPharma moves forward with funds and acquisition

By Emilie Reymond

- Last updated on GMT

Related tags Contract manufacturing Pharmacology

British contract manufacturing organisation (CMO) NextPharma
Technologies has announced a €30m fundraising round and the
acquisition of Bioserv, another CMO based in the US.

The company said that the majority of the funds raised - €16m - will be invested in expanding the company's capabilities in injectable cytotoxic medicines manufacturing. The investment will more than double the capacity of its facility in Braine L'Alleud, Belgium which will be ready to offer this type of service to customers in North America, Europe and Japan in 2009. This cash injection comes on the heels of the recent development of a sterile product development centre at the Belgian site where the company plans to manufacture clinical supplies of cytotoxic and biologic drugs, and which should be up and running in September. Furthermore, NextPharma has agreed to acquire Californian firm Bioserv to boost its existing sterile manufacturing capabilities in Belgium with the expansion of its contract manufacturing business to North America. "The acquisition of Bioserv will create a platform to grow our sterile business in the US,"​ said Bill Wedlake, NextPharma CEO. Although, financial terms of the acquisition were not disclosed, NextPharma could have bagged itself an attractive deal as Bioserv provides a range of services including aseptic and non-aseptic bulk formulation, filtration, filling and lyophilisation services as well as packaging, labelling, validation, and cold chain storage. Over the last few years, contract manufacturing has grown and drug companies are now much more open to outsourcing injectables. Indeed, the increasing influx of biopharmaceuticals, especially oncology products and sterile injectables, has created many opportunities for specialised manufacturing technologies that are usually not available with biopharmaceutical companies. Compared to solid dose contract manufacturing, the injectables market is a lot less competitive because there are only a few players with the capabilities and expertise required to serve big pharma and biotech clients. Lyophilisation, in particular, is a process that is in growing demand in the biopharmaceuticals segment, as it requires a high degree of automation, and CMOs are focusing on tapping this large demand for such specialised niche technologies.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

cGMP Assurance of Supply Services Case Study

cGMP Assurance of Supply Services Case Study

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Apr-2023 | Case Study

Having the right raw materials available for production when they’re needed is imperative, as delays can negatively impact production schedules. Manufacturers...

Related suppliers

Follow us


View more